Open AccessDouble-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer
Author(s) -
Toni K. Choueiri,
Robert W. Ross,
Susanna Jacobus,
Ulka N. Vaishampayan,
Evan Y. Yu,
David I. Quinn,
Noah M. Hahn,
Thomas E. Hutson,
Guru Sonpavde,
Stephanie Morrissey,
Geoffrey Buckle,
William Y. Kim,
Daniel P. Petrylak,
Christopher W. Ryan,
Mario A. Eisenberger,
Amir Mortazavi,
Glenn J. Bubley,
MaryEllen Taplin,
Jonathan E. Rosenberg,
Philip W. Kantoff
Publication year - 2012
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/7hsf-zt65
Subject(s) - docetaxel , vandetanib , medicine , urothelial cancer , oncology , placebo , double blind , urology , chemotherapy , cancer , bladder cancer , pathology , tyrosine kinase , alternative medicine , receptor